Allogene Therapeutics, Inc.
ALLONasdaq
$1.79
0.0%Jul 17 close · end-of-day
Price
1Y↑ +45.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$430.1M
Enterprise Value
$163.2M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
-25.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$173.8M
Free Cash Flow (TTM)
-$109.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-62.3%
ROIC
-1253.4%
Debt / Equity
—
Net Cash
$266.9M
Return 1Y
+44.4%
Company profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
- CEO
- David D. Chang
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 310
- Headquarters
- California
- Website
- allogene.com
Management & directors
- Yoshiyama AnnieSVP, Finance
- Beneski Benjamin MachinasSVP, Chief Technical Officer
- Chang David DPresident and CEO
- Douglas Earl MartinSVP, General Counsel
- Parker Geoffrey M.CHIEF FINANCIAL OFFICER
- Roberts ZacharyEVP of R&D
Roles derived from SEC Form 4 filings.
Earnings
ALLO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.18↓ -35.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $114.1M | $156,000.00 | $95,000.00 | $22,000.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$258.2M | -$180.2M | -$335.5M | -$327.7M | -$273.2M | -$209.3M |
| Net income | -$316.4M | -$182.1M | -$340.4M | -$327.3M | -$257.6M | -$190.9M |
| Diluted EPS | -$2.63 | -$1.34 | -$2.38 | -$2.09 | -$1.32 | -$0.87 |
| Operating cash flow | -$115.1M | -$184.8M | -$220.5M | -$237.7M | -$200.3M | -$149.2M |
| Free cash flow | -$181.1M | -$206.3M | -$225.7M | -$239.2M | -$201.0M | -$149.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Net margin | — | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$71.4M | -$71.8M | -$60.5M | -$65.2M | -$56.8M | -$44.9M | -$42.4M | -$46.1M |
| Net income | -$66.4M | -$66.3M | -$59.9M | -$59.7M | -$50.9M | -$41.4M | -$38.8M | -$42.6M |
| Diluted EPS | -$0.35 | -$0.32 | -$0.27 | -$0.28 | -$0.23 | -$0.19 | -$0.17 | -$0.18 |
| Operating cash flow | -$63.6M | -$44.1M | -$36.7M | -$52.9M | -$39.0M | -$29.7M | -$27.6M | -$12.9M |
| Free cash flow | -$63.6M | -$44.5M | -$37.0M | -$53.0M | -$39.1M | -$29.9M | -$27.6M | -$12.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | Kazam Joshua A | Option exercise | 47,700 | $0.00 | $0.00 | filing |
| 2026-04-21 | Yoshiyama Annie· SVP, Finance | Sale | 9,586 | $2.31 | $22,143.66 | filing |
| 2026-03-31 | Beneski Benjamin Machinas· SVP, Chief Technical Officer | Sale | 2,867 | $2.50 | $7,167.50 | filing |
| 2026-03-16 | Chang David D· President and CEO | Sale | 47,763 | $2.47 | $117,974.61 | filing |
| 2026-03-16 | Beneski Benjamin Machinas· SVP, Chief Technical Officer | Sale | 4,835 | $2.47 | $11,942.45 | filing |
| 2026-03-02 | Beneski Benjamin Machinas· SVP, Chief Technical Officer | Sale | 7,132 | $2.60 | $18,543.20 | filing |
| 2026-02-02 | Chang David D· President and CEO | Sale | 95,269 | $1.80 | $171,484.20 | filing |
| 2026-02-02 | Roberts Zachary· EVP of R&D | Sale | 35,700 | $1.77 | $63,189.00 | filing |
| 2026-02-02 | Parker Geoffrey M.· CHIEF FINANCIAL OFFICER | Sale | 24,001 | $1.76 | $42,241.76 | filing |
| 2026-02-02 | Douglas Earl Martin· SVP, General Counsel | Sale | 22,900 | $1.76 | $40,304.00 | filing |
| 2026-02-02 | Beneski Benjamin Machinas· SVP, Chief Technical Officer | Sale | 7,549 | $1.73 | $13,059.77 | filing |
| 2026-02-02 | Yoshiyama Annie· SVP, Finance | Sale | 4,167 | $1.72 | $7,167.24 | filing |
| 2026-01-21 | Roberts Zachary· EVP of R&D | Sale | 26,269 | $1.56 | $40,979.64 | filing |
| 2025-12-18 | Kazam Joshua A | Option exercise | 47,700 | $0.00 | $0.00 | filing |
| 2025-11-17 | Beneski Benjamin Machinas· SVP, Chief Technical Officer | Sale | 786 | $1.22 | $958.92 | filing |
| 2025-10-21 | Parker Geoffrey M.· CHIEF FINANCIAL OFFICER | Sale | 36,744 | $1.26 | $46,168.84 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.